#152089

MCF7/TAMR-1 Cell Line

Please Enter Your Email ID
Email ID

Cat. #152089

MCF7/TAMR-1 Cell Line

Cat. #: 152089

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 3-5 days

Organism: Human

Tissue: Breast

Disease: Cancer

Model: Tumour line

£800.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne Lykkesfeldt

Institute: Danish Cancer Society, Denmark

Primary Citation: Lykkesfeldt et al. 1986. Br J Cancer. 53(1):29-35. PMID: 3947513

Tool Details
Target Details
Applications
Handling
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: MCF7/TAMR-1 Cell Line
  • Alternate name: MCF-7/TAMR-1; MCF7/TAMR-1; MCF7 TAMR-1; MCF-7/TAM(R)-1; MCF7-TAMR; TAMR-1; TamR-1; TamR1; AL-1
  • Cancer: Breast cancer
  • Cancers detailed: Breast cancer;Tamoxifen resistant
  • Research fields: Cancer;Drug development
  • Tool sub type: Continuous
  • Parental cell: MCF7/S0.5 Cell Line
  • Organism: Human
  • Gender: Female
  • Tissue: Breast
  • Donor: Female; 69 y.o., Caucasian
  • Disease: Cancer
  • Model: Tumour line
  • Crispr: No
  • Receptors of note: Oestrogen receptor positive and progesterone receptor negative
  • Description: MCF7/TAMR-1 cell line is a stable tamoxifen-resistant subline. This cell line has been established in tissue culture after long term treatment with 1 uM tamoxifen. Tamoxifen (Nolvadex) is a widely used drug for hormone-dependent cancer. Tamoxifen resistance (either primary or acquired) makes oestrogen receptor-positive breast cancer much more difficult to treat. This cell line was produced from the parental cell line MCF7/S0.5, as a model cell system to study the effects of tamoxifen resistant cancer growth. MCF7/TAMR-1 cells are oestrogen receptor positive and progesterone receptor negative. They are growth inhibited by the pure antioestrogen fulvestrant.Previous applications of this cell line include treatment with steroidal antiestrogens. MCF7/TAMR-1 enables identification of new hormone therapies and greater understanding of the signalling pathways/methods behind tamoxifen resistance. Additionally MCF/TAMR-1 can aid in identifying new predictive markers for response to hormonal therapy.
  • Application: New hormone therapies identification; Elucidating signaling pathways involved in tamoxifen-resistant cancer growth
  • Production details: The parental cell line for the MCF7/TAMR-1 cells is MCF7/S0.5, which was adapted to grow at low serum concentration in order to study the effect of estradiol and tamoxifen. MCF7/TAMR-1 has been established from a clone of cells that survived long term treatment with 1 uM tamoxifen. The establishment of the MCF7/TAMR-1 cell line, originally named AL-1, was first described in Lykkesfeldt et al (1986). Tamoxifen-resistant cells are passaged continuously in presence of 1 uM tamoxifen, which is le...
  • Biosafety level: 1
  • Additional notes: During the establishment process the treatment of MCF7/S0.5 cells with tamoxifen was started in passage 351. Few colonies of cells survived the treatment and after 28 days of tamoxifen treatment, tamoxifen was omitted from the medium for 22 days. After 19 passages without tamoxifen (passage 372) the cells underwent a second treatment with tamoxifen which initially reduced cell growth rate, but around 390-400 the growth rate of the tamoxifen resistant cell lines was close to the growth rate of...
  • Recommended controls: MCF7-S0.5 parental line
  • Cellosaurus id: CVCL_M436

Target Details

  • Target: Oestrogen receptor

Applications

  • Application: New hormone therapies identification; Elucidating signaling pathways involved in tamoxifen-resistant cancer growth
  • Application notes: Points of Interest Estrogen receptor-positive breast cancer is the most common form of breast cancer, with approximately 80% of all breast cancers expressing the estrogen receptor (ER). They depend on the estrogen hormone to facilitate the growth and expansion of cancer cells. Hormone therapy (e.g. tamoxifen) can limit the growth of ER breast cancers by blocking the actions of estrogen. Tamoxifen resistance (either primary or acquired) makes ER+ breast cancer much more difficult to treat. MCF7/TAMR-1 cell line is able to survive with tamoxifen in growth medium, allowing the resistance to be understood and prospective new treatment options to be discovered. MCF7/TAMR-1 cells are oestrogen receptor positive and progesterone receptor negative. MCF7/TAMR-1 cells are growth inhibited by the pure antioestrogen fulvestrant. The oestrogen receptor is a major driver of growth of MCF7/TAMR-1 cell. Treatment targeting the Aurora kinase A restores sensitivity to tamoxifen treatment. The TAMR lines were established from the MCF7/S0.5 cell line, which was adapted to grow with 0.5% fetal calf serum in phenol red containing DMEM/F12 medium. Treatment with tamoxifen was started in passage 351. Few colonies of cells survived the treatment and after 28 days of tamoxifen treatment, tamoxifen was omitted from the medium for 22 days. After 19 passages without tamoxifen (passage 372) the cells underwent a second treatment with tamoxifen which initially reduced cell growth rate, but around 390-400 the growth rate of the tamoxifen resistant cell lines was close to the growth rate of the parental MCF7/S0.5 cells. Passage 431 (AL3502, AL3503) Concentration Vial has between 1-5 million cells as standard, however this may vary.

Handling

  • Format: Frozen
  • Passage number: 431 (AL3502, AL3503)
  • Growth medium: Phenol red-free DMEM/F-12 containing 1% Fetal bovine serum, 2 mM Glutamax and 6 ng/ml Insulin. To maintain high-level resistance, the medium should be supplemented with 1 uM Tamoxifen
  • Temperature: 37° C
  • Atmosphere: 5% CO2
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes

Related Tools

  • Related tools: MCF7/S0.5 Cell Line

References

  • Lee et al. 2018. Autophagy. 14(5):812-824. PMID: 29130361
  • Martin et al. 2017. Nat Commun. 8(1):1865. PMID: 29192207
  • Guney Eskiler et al. 2016. Cell Biol Toxicol. :. PMID: 27585693
  • Joshi et al. 2016. Oncotarget. :. PMID: 27528030
  • Leclercq et al. 2016. J Recept Signal Transduct Res. :1-18. PMID: 27400858
  • Guest et al. 2016. PLoS One. 11(6):e0157397. PMID: 27308830
  • Alves et al. 2016. Clin Cancer Res. :. PMID: 27252418
  • Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755
  • Elias et a...